Bladder cancer (BC) ranks as the tenth most prevalent cancer in the world (IARC, WHO), with a steady rise in its incidence and prevalence, and is accompanied by a high morbidity and mortality. The current standard of care to diagnose bladder cancer is cystoscopy, which consists of inserting a camera in the urinary track to the bladder. Although the detection rate is high, the technique/equipment is expensive, invasive, unavailable worldwide, and, most importantly, uncomfortable and associated with risk of complications. Therefore, there is a critical need to establish a non-invasive, low cost, and sensitive method for the early detection and monitoring of BC. In this project, we aim to investigate the robustness of using urine biomarkers as a diagnostic tool in different populations through a large international multicentre study (Canada, France, Germany). This would demonstrate the applicability of such tests to be used as universal non-invasive biomarkers for early detection and surveillance of BC in different populations to reduce the number of procedures, improve the patients’ quality of life and lower the costs.